GLP-1s (glucagon-like peptide-1 receptor agonists), like Wegovy, Ozempic, or generic liraglutide, have helped you reach your ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life improvements occurring despite minimal weight changes.

Medications such as Ozempic and Saxenda have grown in popularity due to their ability to treat type 2 diabetes and assist in ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Liraglutide — sold under the brand names Victoza and Saxenda — is part of a class of GLP-1 drugs that treat obesity and Type 2 diabetes by decreasing appetite. Ozempic is part of this group.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1) and acts as a GLP-1 receptor agonist. Several large, randomized, multicenter phase 3 trials evaluated the efficacy ...

In a randomized trial of 2.4-mg semaglutide, 3.0-mg liraglutide, and matching placebo for both, those on semaglutide plus diet and exercise saw a 9.4% greater average loss in baseline weight ...

The cost of Saxenda (liraglutide’s brand name) varies depending on treatment plan, insurance coverage and pharmacy, but according to Novo Nordisk, the monthly list price of the drug is $1,349.02.

Liraglutide was approved by the US Food and Drug Administration in 2014 to help adults lose weight. In 2020, that approval was extended to children ages 12 to 17. The study was published Tuesday ...

Children with obesity receiving once-daily liraglutide 3 mg had a greater reduction in BMI at 56 weeks than those receiving placebo, according to data presented at the European Association for the ...

However, liraglutide trended towards fewer events versus the other three agents. Liraglutide was significantly better than sitagliptin when it came to the development of any CV disease.